Bank of America (FEED) reports 14-share holding; immaterial stake disclosed

Rhea-AI Filing Summary

ENvue Medical, Inc. reports an amended Schedule 13G showing 0.0% ownership by Bank of America Corporation. The filing states 14 shares beneficially owned with 14 shares of shared voting and dispositive power. The beneficial ownership calculation cites December 5, 2025 outstanding share totals of 1,088,192 from a Form 424B3 prospectus.

Insights

Corporate Governance Analyst

Small broker/depository holding reported; no control implications.

Bank of America Corporation reports beneficial ownership of 14 shares with shared voting and dispositive power, amounting to 0.0% of the class based on the cited December 5, 2025 share count.

The position size is de minimis relative to the issuer's reported 1,088,192 outstanding shares; this filing reflects routine disclosure by a parent and its subsidiaries rather than an indication of strategic influence.

Equity Markets Analyst

Holding is immaterial to market liquidity or control.

The filing lists 14 shares beneficially owned and attributes voting/dispositive authority as shared. The calculation references a prospectus share total as of December 5, 2025.

Given the 0.0% stake, there is no material dilution or overhang signaled; trading or corporate action effects are not indicated in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 01:27 PM Learn about SEC filing dates

FAQ

What does Bank of America report owning in ENvue Medical (FEED)?

Bank of America reports beneficial ownership of 14 shares in ENvue Medical. The filing states shared voting and dispositive power for those 14 shares and calculates ownership versus 1,088,192 outstanding shares as of December 5, 2025.

What percentage of ENvue Medical does the filing say is owned by Bank of America?

The filing reports ownership equal to 0.0% of the class. That percentage is derived using the prospectus figure of 1,088,192 outstanding shares dated December 5, 2025 as referenced in the amendment.

Does the Schedule 13G/A indicate Bank of America has voting control over FEED shares?

The filing shows shared voting power for 14 shares, with no sole voting power reported. It lists 14 shared dispositive and voting rights rather than exclusive control of the class.

Which subsidiaries are named in the filing for Bank of America on FEED?

The statement is filed on behalf of Bank of America Corporation and its wholly owned subsidiaries BofA Securities, Inc. and Bank of America N.A. These entities are identified in Item 7 of the amendment.

What date does the amendment use for the outstanding share count for FEED?

The amendment cites the Form 424B3 prospectus reporting outstanding shares as of December 5, 2025. That prospectus was filed on December 18, 2025, per the amendment's comment.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

ENvue Medical, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

02/27/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP Number(s):

1

Names of Reporting Persons

BANK OF AMERICA CORP /DE/

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 14.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 14.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

14.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

HC

Comment for Type of Reporting Person: The beneficial ownership calculation relies on the 1,088,192 outstanding shares disclosed in the Form 424B3 - Prospectus by the issuer on December 18, 2025, which reports share totals as of December 5, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ENvue Medical, Inc.
(b)	Address of issuer's principal executive offices: 969 PRUITT AVE,, 969 PRUITT AVE,, TYLER, TEXAS, 77569.
Item 2.
(a)	Name of person filing: BANK OF AMERICA CORP /DE/
(b)	Address or principal business office or, if none, residence: 100 N TRYON ST CHARLOTTE, NC 28255
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 63008J884
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 14.00
(b)	Percent of class: 0.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0.00
	(ii) Shared power to vote or to direct the vote: 14.00
	(iii) Sole power to dispose or to direct the disposition of: 0.00
	(iv) Shared power to dispose or to direct the disposition of: 14.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement on Schedule 13G is being filed by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o); and Bank of America N.A., a bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BANK OF AMERICA CORP /DE/

Signature:	/s/ Monica Yako
Name/Title:	Authorized Signatory
Date:	03/06/2026